Literature DB >> 10192234

Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Témoins sur l'Infarctus du Myocarde (ECTIM) Study.

V Nicaud1, O Poirier, I Behague, S M Herrmann, C Mallet, A Troesch, J Bouyer, A Evans, G Luc, J B Ruidavets, D Arveiler, A Bingham, L Tiret, F Cambien.   

Abstract

Endothelin-1 is a potent vasoconstrictor that has also mitogenic properties, stimulating the synthesis and secretion of several vasoactive molecules. There is much evidence to suggest that endothelin-1 might be involved in the pathogenesis of hypertension, atherosclerosis, and ischemic heart disease. Endothelin-1 exerts its effects through at least two receptors, ET(A) and ET(B), which are encoded by different genes and have separate tissue distributions and biologic properties. The objective of this study was to identify polymorphisms of the ET(A) and ET(B) receptor genes and to study their association with myocardial infarction (MI) and blood pressure. The coding regions and 1.3 kb upstream of the ET(A) and ET(B) receptor genes were explored by polymerase chain reaction/single strand conformation polymorphism. Six polymorphisms were found in the ET(A) receptor gene and three in the ET(B) receptor gene. Most of these polymorphisms were frequent. Associations between the detected polymorphisms, blood pressure, and MI were examined in the ECTIM study, a multicenter study comparing 652 patients having survived an MI and 773 controls from Belfast (Northern Ireland) and France. Alleles at the different polymorphic sites were similarly distributed in patients with MI and controls. Allele frequencies were similar in both countries, except for the ET(A)/-231 G allele, which appeared more frequently in France than in Belfast (P < .01). The mean systolic and diastolic blood pressure levels did not significantly differ between genotypes. However, a C/T substitution located in the nontranslated part of exon 8 of the ET(A) receptor gene (ET(A)/EX8nt1363) was associated with pulse pressure (P < .005). These results do not support an involvement of the endothelin receptor genes in a predisposition to MI or the determination of blood pressure levels, but suggest that a polymorphism of the ET(A) receptor gene might influence the pulse pressure. This result will have to be confirmed in other studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192234     DOI: 10.1016/s0895-7061(98)00255-6

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

Review 3.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 4.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

Review 5.  ET-1 actions in the kidney: evidence for sex differences.

Authors:  W Kittikulsuth; J C Sullivan; D M Pollock
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity.

Authors:  Rebecca Darrah; Edward McKone; Clare O'Connor; Christine Rodgers; Alan Genatossio; Sharon McNamara; Ronald Gibson; J Stuart Elborn; Madeleine Ennis; Charles G Gallagher; Noor Kalsheker; Moira Aitken; Dawn Wiese; John Dunn; Paul Smith; Rhonda Pace; Douglas Londono; Katrina A B Goddard; Michael R Knowles; Mitchell L Drumm
Journal:  Physiol Genomics       Date:  2009-12-22       Impact factor: 3.107

7.  Endothelin-1 and endothelin receptor gene variants and their association with negative outcomes following aneurysmal subarachnoid hemorrhage.

Authors:  Matthew Gallek; Sheila Alexander; Elizabeth Crago; Paula Sherwood; Michael Horowitz; Samuel Poloyac; Yvette Conley
Journal:  Biol Res Nurs       Date:  2012-09-19       Impact factor: 2.522

8.  Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.

Authors:  Matthew R G Taylor; Dobromir Slavov; Kurt Humphrey; Lan Zhao; Jennifer Cockroft; Xiao Zhu; Philip Lavori; Michael R Bristow; Luisa Mestroni; Laura C Lazzeroni
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

9.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

10.  Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.

Authors:  Raymond L Benza; Mardi Gomberg-Maitland; Teresa Demarco; Adaani E Frost; Adam Torbicki; David Langleben; Tomas Pulido; Priscilla Correa-Jaque; Michael J Passineau; Howard W Wiener; Mayumi Tamari; Tomomitsu Hirota; Michiaki Kubo; Hemant K Tiwari
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.